Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Optimizing your results on semaglutide with niacinamide The compound is only one piece of the puzzle
GLP-1 has been shown to counter the effects of both mechanisms responsible for type 2 diabetes by stimulating glucose dependent pancreatic beta-cell function as well as inhibiting the effects of pancreatic alpha-cells
Payment flexibility includes HSA and FSA eligibility, allowing you to use pre-tax healthcare savings accounts if you have them
GLP-1 7-36 is a 30 amino acid peptide derived from the proglucagon molecule that is synthesised in intestinal L cells, as well as in alpha cells of the pancreas and in neuronal clusters of the central nervous system (CNS).2 It is a peptide with a short half-life (23 min), due to rapid renal clearance and degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which converts GLP-1 into GLP-1 9-36, a form that does not interact with the GLP-1 receptor.1 The GLP-1 receptor (GLP-1R) belongs to the class B G protein-coupled glucagon receptor family.2,3 Activation of the Gs subunit leads to stimulation of adenylate cyclase, synthesis of cyclic AMP, mobilisation of intracellular calcium, and glucose-dependent insulin release by pancreatic beta cells.2,3 Intracellular signalling also involves various additional pathways, such as recruitment of beta-arrestin-1, which modulates receptor internalisation and desensitisation, as well as the effects of certain GLP-1R agonists.3,4 Depending on the structure of the ligand, intracellular signalling pathways are modulated towards cyclic AMP generation, activation of kinase cascades (ERK), and beta-arrestin-1 recruitment, all of which influence the biological effect and desensitisation of the GLP-1 receptor.4 Some GLP-1R agonists exhibit biased agonism, favouring intracellular activation of cyclic AMP with reduced beta-arrestin recruitment, which results in less GLP-1R desensitisation and a more prolonged biological action (Table 1)
References Forloni G, et al
Heart health: Early research suggests that both drugs may have some heart benefits, but more studies are needed to fully understand how they affect heart health in the long term
